Drug
Molnupiravir clinical trials
Also written MK-4482 and EIDD-2801.
- studies test it
- 24
- open now
- 7
- in phase 3
- 8
- first study started
- 2020
Keep track of what changes. Save the molnupiravir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2020 | 7 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 11
- Phase 3
- 8
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 11
Who runs them
Industry 15 · Other 9
Merck Sharp & Dohme LLC (10) · University of Oxford (4) · Ridgeback Biotherapeutics, LP (3) · University of Witwatersrand, South Africa (1) · Geropharm (1) · Valenta Pharm JSC (1) · Promomed, LLC (1) · Oxford University Clinical Research Unit, Vietnam (1)
Often tested with
Tested in the same studies.
Favipiravir (4) · Nirmatrelvir and ritonavir drug combination (3) · Remdesivir (2) · Nitazoxanide (2) · Hydroxychloroquine (2) · Sotrovimab (2) · Baloxavir (2) · Oseltamivir (2)
Studies
Open first, then newest update. How each study uses molnupiravir is read from its arms, and is right about nine times in ten.
Testing it · 24
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06667700Written as Molnupiravir
- Adaptive Dengue Antiviral Platform TrialRecruitingPhase 2Oxford University Clinical Research Unit, VietnamNCT06551844Written as Molnupiravir 400 mg
- AGILE (Early Phase Platform Trial for COVID-19)RecruitingPhase 1/2University of LiverpoolNCT04746183Written as CST-2: EIDD-2801
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as Molnupiravir
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaRecruitingPhase 2University of OxfordNCT05648448Written as Molnupiravir
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
- Assessing Antiviral Treatments in Early Symptomatic RSVRecruitingPhase 2University of OxfordNCT06488300Written as Molnupiravir
- A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT06816030Written as MK-4482
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)CompletedPhase 1Merck Sharp & Dohme LLCNCT05818124Written as Molnupiravir
- Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)CompletedPhase 2Merck Sharp & Dohme LLCNCT05559905Written as Molnupiravir
- A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)CompletedPhase 1Merck Sharp & Dohme LLCNCT06615869Written as Molnupiravir
- A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South AfricaCompletedPhase 2/3University of Witwatersrand, South AfricaNCT05459532Written as Molnupiravir 200 mg
- A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)CompletedPhase 1Merck Sharp & Dohme LLCNCT05386589Written as Molnupiravir
- A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT05386758Written as Molnupiravir
- Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)CompletedPhase 3Merck Sharp & Dohme LLCNCT04939428Written as Molnupiravir
- Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)CompletedNot applicableGeropharmNCT05648799Written as GP30341 capsules 200 mg
- Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy VolunteersCompletedNot applicableValenta Pharm JSCNCT05412173Written as Molnupiravir
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT04575597Written as Molnupiravir
- The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)CompletedPhase 2Ridgeback Biotherapeutics, LPNCT04405739Written as EIDD-2801
- Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)TerminatedPhase 2/3Merck Sharp & Dohme LLCNCT04575584Written as Molnupiravir
Codes
What other systems call molnupiravir · ClinicalTrials.gg INT001256
- MeSH (NLM) C000656703molnupiravirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YA84KI1VEWMOLNUPIRAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2587901One source FDA
- Wikidata Q96376832molnupiravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C172633MolnupiravirOne source FDA
- DrugBank DB15661One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656703 | molnupiravir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YA84KI1VEW | MOLNUPIRAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587901 | — | One source FDA |
| Wikidata | Q96376832 | molnupiravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C172633 | Molnupiravir | One source FDA |
| DrugBank | DB15661 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.